Every 8-K that CNS Pharmaceuticals (CNSP) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CNSP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CNSP filings page.
CNS Pharmaceuticals, Inc. used this report to share an updated investor presentation describing a major strategic pivot and recent financing. The company is shifting its focus toward high‑value oncology and neurology markets, targeting novel, differentiated assets with clear development pathways and near‑term clinical or regulatory milestones.
The presentation highlights a $22.5 million private placement completed in May 2026, described as a top‑performing PIPE for the first half of 2026. The deal included 650,000 common shares and 9,143,479 pre‑funded warrants, providing capital to acquire clinical‑stage assets and pursue an asset‑in‑licensing strategy. As of June 30, 2026, common stock outstanding was 1,461,449 shares, and assuming exercise of all pre‑funded warrants, the pro forma fully diluted market capitalization is presented as approximately $50.7 million.
Management emphasizes a purpose‑built executive team with deep experience in oncology, neurology and rare diseases, and outlines plans to out‑license legacy glioblastoma programs while searching globally for underfunded or shelved clinical‑stage assets. The capital structure is described as clean, with no debt, preferred or convertible securities, and pre‑funded warrants subject to 4.99% and 9.99% beneficial ownership caps.
CNS Pharmaceuticals, Inc. entered into a private placement with institutional investors, selling 650,000 shares of common stock at $2.30 per share and issuing pre-funded warrants for 9,143,479 shares at $2.299 per warrant. Gross proceeds are expected to be approximately $22.5 million before fees.
The pre-funded warrants are exercisable immediately at $0.001 per share, subject to a 4.99% or 9.99% beneficial ownership cap, and remain outstanding until fully exercised. The company plans to use net proceeds to identify, acquire, and advance new assets and for working capital and general corporate purposes.
CNS Pharmaceuticals agreed to register the resale of the shares and underlying warrant shares and accepted restrictions on additional equity sales and variable rate transactions for specified periods. The company also announced the resignation of director Jerzy (George) Gumulka and the appointment of life sciences executive Michal Fisher as an independent board member.
CNS Pharmaceuticals, Inc. furnished an investor presentation outlining a new corporate growth strategy led by a recently installed executive team. The company is pivoting to focus on high-value neurology and oncology markets, emphasizing data-driven, capital-efficient development and targeting assets with strong biological rationale and near-term catalysts.
The strategy includes a formal global search for differentiated preclinical and clinical-stage programs, while positioning legacy glioblastoma multiforme programs such as Berubicin and TPI 287 for potential out-licensing. Management highlights neurology and oncology as large, growing therapeutic areas with significant unmet needs and active deal flow.
CNS Pharmaceuticals has appointed Dr. Lynne Kelley as Chief Medical Officer effective March 2, 2026. Her employment agreement includes a base salary of $450,000, an annual bonus target equal to 40% of base salary, and eligibility for future equity grants determined by the board’s Compensation Committee.
Dr. Kelley will also receive an initial grant of 9,500 restricted stock units, vesting 25% after six months, 25% after twelve months, and the remaining 50% in twelve quarterly installments, subject to continued employment. If she is terminated without cause or resigns for good reason, she is entitled to six months of base salary, a pro-rated target bonus, and accelerated vesting of all unvested equity, subject to a release of claims and covenant compliance.
The company also entered into a separation and severance agreement with former Chief Medical Officer Dr. Sandra Silberman, providing severance equal to three months of her current annualized base salary, paid in three monthly installments.
CNS Pharmaceuticals, Inc. is changing its finance leadership, appointing Steve O’Loughlin as Chief Financial Officer effective March 2, 2026, under a new employment agreement. His compensation includes a $450,000 base salary, a target annual bonus equal to 40% of base salary, and eligibility for equity grants. He will also receive 9,500 restricted stock units that vest over roughly three years, starting six months after his start date, and severance and bonus protections if he is terminated without cause or resigns for good reason.
Current Chief Financial Officer Christopher Downs will resign from that role and become Senior Vice President – Finance on March 2, 2026, under a separate agreement providing a $350,000 base salary, a 30% target bonus, equity eligibility, and six months of salary as severance if he is terminated without cause or leaves for good reason.
CNS Pharmaceuticals, Inc. is appointing Rami Levin as its new Chief Executive Officer and President effective January 1, 2026, following the resignation of John Climaco on December 16, 2025. Levin will also join the Board of Directors on January 1, 2026.
Levin’s employment agreement sets an initial annual base salary of $580,000, a target annual bonus equal to 50% of base salary based on goals set by the Compensation Committee, and eligibility for annual equity grants. He will receive an initial grant of 19,000 restricted stock units, vesting 25% after six months, 25% after twelve months, and the remaining 50% in twelve quarterly installments, subject to continued employment. If terminated without cause or if he resigns for good reason, he is entitled to 12 months of base salary, a target bonus for the post-year-end period, and accelerated vesting of all unvested equity, subject to a release and covenants.
Under a separation agreement, Climaco will receive 12 months of his current annualized base salary in monthly installments, salary through December 31, 2025, his 2025 cash bonus of $319,000 paid over 12 months, and 12 months of employer-paid COBRA premiums, conditioned on his execution and compliance with the agreement.
CNS Pharmaceuticals, Inc. reported results of its 2025 annual stockholder meeting and related corporate changes. Stockholders approved an amendment to the company’s Amended and Restated Articles of Incorporation to increase authorized common stock from 25,000,000 shares to 300,000,000 shares and authorized preferred stock from 416,667 shares to 5,000,000 shares, and the company filed the amendment in Nevada to make these changes effective. They also approved amendments to the 2020 Equity Plan, raising the number of shares of common stock that may be issued under the plan to 115,061 shares.
All director nominees were elected to serve until the 2026 annual meeting, the appointment of MaloneBailey, LLP as independent auditor for the year ending December 31, 2025 was ratified, and executive compensation was approved on an advisory basis. Stockholders recommended holding the advisory say‑on‑pay vote every year, and the board chose an annual frequency in line with that recommendation. As of the October 10, 2025 record date, 574,580 shares of common stock were issued and outstanding, with 204,107 shares represented at the meeting, constituting a quorum.